Cart
sales@molnova.com
Choline theophyllinate
CAS No. 4499-40-5
Choline theophyllinate( —— )
Catalog No. M33317 CAS No. 4499-40-5
Choline theophyllinate (Oxtriphylline) is the choline salt of theophylline, a small molecule PDE inhibitor that can be used to treat immune system disorders and respiratory disorders, and to study asthma disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 29 | Get Quote |
|
| 10MG | 43 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCholine theophyllinate
-
NoteResearch use only, not for human use.
-
Brief DescriptionCholine theophyllinate (Oxtriphylline) is the choline salt of theophylline, a small molecule PDE inhibitor that can be used to treat immune system disorders and respiratory disorders, and to study asthma disorders.
-
DescriptionCholine theophyllinate (Oxtriphylline) is a choline salt of theophylline with anti-asthmatic activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE | Endogenous Metabolite
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number4499-40-5
-
Formula Weight283.33
-
Molecular FormulaC12H21N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 250 mg/mL (882.36 mM; Ultrasonic)
-
SMILESO=C1C=2[N-]C=NC2N(C(=O)N1C)C.OCC[N+](C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Brumlik J, Theophylline compounds and myasthenia gravis. II. Clinical report of nine cases. Clin Pharmacol Ther. 1973 May-Jun;14(3):380-5.?
molnova catalog
related products
-
Enpp-1-IN-14
ENPP1-IN-2 is a potent inhibitor of Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) with an IC50 value of 32.38 nM for recombinant human ENPP-1. ENPP1-IN-2 has anti-tumor activity.
-
Cudetaxestat
Cudetaxestat (BLD-0409) is a potent, orally active autotaxin inhibitor.
-
PDE10-IN-1
PDE10-IN-1 is PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1 for treating CNS and metabolic disorders.
